Endpoints News

Merck is keen for more M&A		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T W Th Fri

4 September, 2026

Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.

presented by

How the Riyadh Global Medical Biotechnology Summit is de-risking Saudi Arabia's cell and gene therapy ambitions

news

Italy's Menarini gets into obesity with European rights to GLP-1 from China's Gan & Lee

Merck's M&A chief expects 'a lot more deal flow' as Keytruda patent cliff nears

Take the Q3 Biopharma Sentiment Survey (BPSI)

Sep 10

11:00 am ET

Inside the IDMO model: Analytical comparability, regulatory readiness and operational excellence

in case you missed it

AbbVie claims Phase 3 win of multiple myeloma drug, seeking to enter crowded market

GSK to license Hutchmed’s dual-action cancer drug for $110M upfront

News Briefing

Pfizer shares ADC rights with Medicus; RevMed updates lung cancer data

Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trial

Superluminal secures $60M for Phase 1 of genetic obesity drug

In Focus

China deaths reignite debate about using viruses to deliver CRISPR therapies

RFK Jr. is investigating whether troops died of Covid vaccine, Army doctor says

Buried underpants and a new definition of kissing win 2026 Ig Nobel prizes

A couple of things to note: Our Peer Review column looking at people's job moves is on a break this week, but it'll return next Friday. And Monday is Labor Day, so Endpoints won't be publishing any newsletters. We'll be back Tuesday — enjoy the long weekend!